China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma, Inc., to evaluate Umoja’s iCIL platform with IASO’s best-in-class chimeric antigen receptors (CARs). The collaboration aims to develop off-the-shelf therapies for patients with hematological malignancies, initially focusing on acute myeloid leukemia (AML), with the goal of increasing patient access. Financial details of the agreement were not disclosed.
IASO Bio Profile
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform IMARS, high-throughput CAR T drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. The company has a diversified portfolio of over 10 novel pipeline products, including its leading asset, Equecabtagene Autoleucel (CT103A), a fully human BCMA chimeric antigen receptor autologous T cell injection.
Umoja Bio Profile
Umoja Bio boasts integrated cellular immunotherapy technologies, including the VivoVec off-the-shelf in vivo delivery platform, iCIL off-the-shelf cell therapy platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. These technologies are designed to enhance the delivery and efficacy of cell therapies, making them more accessible to patients.
Future Implications
This collaboration between IASO Bio and Umoja Biopharma represents a significant step forward in the development of off-the-shelf therapies for hematological malignancies. By combining their respective strengths, the companies aim to accelerate the development and commercialization of innovative treatments, ultimately improving patient outcomes and access to care.-Fineline Info & Tech
